Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Mednax

Related MD
Events for the Week of Nov. 17-21, 2014
Top 4 NYSE Stocks In The Specialized Health Services Industry With The Highest Profit Margin

In a report published Wednesday, Jefferies & Company reiterated its Buy rating on Mednax (NYSE: MD), and raised its price target from $81.00 to $88.00.

Jefferies noted, “MD is one of our top picks given our belief that the company's push to aggressively expand its anesthesiology business (which we expect mgmt to highlight at today's analyst day) will drive robust growth over the next several years that is not yet adequately reflected in the stock's valuation. Our positive bias is also driven by MD's highly defensive (i.e., benign) reimbursement outlook. Reiterate Buy/PT to $88.”

Mednax closed on Tuesday at $75.29.

Latest Ratings for MD

DateFirmActionFromTo
Oct 2014CitigroupMaintainsBuy
Oct 2014BairdInitiates Coverage onOutperform
Sep 2014SunTrust Robinson HumphreyInitiates Coverage onNeutral

View More Analyst Ratings for MD
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (MD)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga Professional